Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis.
- Author:
Seok Hwan KIM
1
;
Sunhee JANG
;
Yegyu SUNG
;
Jun Kyu PARK
;
Yunjung PARK
;
Jintak YUN
;
Sang Bum KANG
Author Information
- Publication Type:Case Report
- Keywords: Inflammatory bowel disease; Ulcerative colitis; Pulmonary thromboembolism; Rivaroxaban; Cytomegalovirus
- MeSH: Adult; Anticoagulants; Colitis*; Colitis, Ulcerative*; Crohn Disease; Cytomegalovirus*; Female; Follow-Up Studies; Ganciclovir; Gastrointestinal Tract; Heparin, Low-Molecular-Weight; Humans; Inflammatory Bowel Diseases; Mesalamine; Pulmonary Embolism*; Recurrence; Rivaroxaban; Superinfection; Ulcer*; Venous Thromboembolism; Vitamin K
- From:The Korean Journal of Gastroenterology 2017;70(1):44-49
- CountryRepublic of Korea
- Language:English
- Abstract: Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous thromboembolism. Thromboembolic complications, particularly pulmonary thromboembolism, can be life threatening and require prompt management with anticoagulants. Conventional vitamin K antagonists have been used for the treatment of thromboembolic complications, but the development of novel oral anticoagulants has shifted the paradigm. We report a case of a 42-year-old female with ulcerative colitis who experienced an acute flare-up due to cytomegalovirus superinfection with pulmonary thromboembolism. She was treated with oral mesalamine, intravenous steroid and ganciclovir and low-molecular-weight heparin, followed by rivaroxaban, a novel oral anticoagulant. Her symptoms resolved after treatment, and no recurrence was noted during a 6-month post-treatment follow-up.
